» Articles » PMID: 32885042

Characterization of Four Subtypes in Morphologically Normal Tissue Excised Proximal and Distal to Breast Cancer

Abstract

Widespread mammographic screening programs and improved self-monitoring allow for breast cancer to be detected earlier than ever before. Breast-conserving surgery is a successful treatment for select women. However, up to 40% of women develop local recurrence after surgery despite apparently tumor-free margins. This suggests that morphologically normal breast may harbor early alterations that contribute to increased risk of cancer recurrence. We conducted a comprehensive transcriptomic and proteomic analysis to characterize 57 fresh-frozen tissues from breast cancers and matched histologically normal tissues resected proximal to (<2 cm) and distant from (5-10 cm) the primary tumor, using tissues from cosmetic reduction mammoplasties as baseline. Four distinct transcriptomic subtypes are identified within matched normal tissues: metabolic; immune; matrisome/epithelial-mesenchymal transition, and non-coding enriched. Key components of the subtypes are supported by proteomic and tissue composition analyses. We find that the metabolic subtype is associated with poor prognosis ( < 0.001, HR6.1). Examination of genes representing the metabolic signature identifies several genes able to prognosticate outcome from histologically normal tissues. A subset of these have been reported for their predictive ability in cancer but, to the best of our knowledge, these have not been reported altered in matched normal tissues. This study takes an important first step toward characterizing matched normal tissues resected at pre-defined margins from the primary tumor. Unlocking the predictive potential of unexcised tissue could prove key to driving the realization of personalized medicine for breast cancer patients, allowing for more biologically-driven analyses of tissue margins than morphology alone.

Citing Articles

Genomes and epigenomes of matched normal and tumor breast tissue reveal diverse evolutionary trajectories and tumor-host interactions.

Zhu B, Tapinos A, Koka H, Yi Lee P, Zhang T, Zhu W Am J Hum Genet. 2024; 111(12):2773-2788.

PMID: 39492056 PMC: 11639081. DOI: 10.1016/j.ajhg.2024.10.005.


Peritumoral tissue (PTT): increasing need for naming convention.

Koca D, Abedi-Ardekani B, LeMaoult J, Guyon L Br J Cancer. 2024; 131(7):1111-1115.

PMID: 39223304 PMC: 11443153. DOI: 10.1038/s41416-024-02828-y.


Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.

Morla-Barcelo P, Laguna-Macarrilla D, Cordoba O, Matheu G, Oliver J, Roca P Breast Cancer Res. 2024; 26(1):89.

PMID: 38831458 PMC: 11145834. DOI: 10.1186/s13058-024-01837-2.


Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response.

Sverchkova A, Burkholz S, Rubsamen R, Stratford R, Clancy T BMC Med Genomics. 2024; 17(1):37.

PMID: 38281021 PMC: 10821267. DOI: 10.1186/s12920-024-01808-8.


Adipose-enriched peri-tumoral stroma, in contrast to myofibroblast-enriched stroma, prognosticates poorer survival in breast cancers.

Lau H, Tan V, Tan B, Sim Y, Quist J, Thike A NPJ Breast Cancer. 2023; 9(1):84.

PMID: 37863888 PMC: 10589339. DOI: 10.1038/s41523-023-00590-7.


References
1.
Rice A, Cortes E, Lachowski D, Cheung B, Karim S, Morton J . Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017; 6(7):e352. PMC: 5541706. DOI: 10.1038/oncsis.2017.54. View

2.
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y . Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J Natl Cancer Inst. 2017; 110(2). PMC: 6298573. DOI: 10.1093/jnci/djx137. View

3.
Tsai S, Clemente-Casares X, Zhou A, Lei H, Ahn J, Chan Y . Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection. Cell Metab. 2018; 28(6):922-934.e4. DOI: 10.1016/j.cmet.2018.08.003. View

4.
Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R . The Reactome pathway Knowledgebase. Nucleic Acids Res. 2015; 44(D1):D481-7. PMC: 4702931. DOI: 10.1093/nar/gkv1351. View

5.
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View